Business
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to host investor webcast highlighting planned commercialization strategy and opportunity for TP-03 in Demodex blepharitis on Thursday, June 15, 2023 IRVINE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the first quarter ended March 31, 2023, and recent business achievements. “We are off to a tremendous start this year highlighted by the progress and execution of our commercial strategy as we prepare for the potential launch of TP-03 in the fall,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “TP-03 has the potential, if approved, to be the first FDA-approved treatment and standard of care for Demodex blepharitis, a prevalent eyelid condition that affects approximately 25 million patients in the United States. We look forward to providing an update on our expected commercial launch plans during our virtual event in June. In tandem, we have continued to advance our broad pipeline into proof-of-concept studies. Enrollment is ongoing in our Phase 2a rosacea trial of TP-04, and we remain on-track to provide readouts from our Phase 2a trials in Lyme disease prevention and Meibomian Gland Disease.” Recent Business Highlights and Corporate Update Demodex Expert Panel on Treatment and Eyelid Health (DEPTH) published two papers on the importance of diagnosis and management of Demodex blepharitis (DB) Eye; https://doi.org/10.1038/s41433-023-02500-4 Clinical diagnosis and management of DB: established consensus about the disease, including signs, symptoms and diagnosisDEPTH consensus regarding current clinical practice management options for DB: collarettes are pathognomonic, patients with >10 collarettes should be treated even in the absence of symptoms; efficacy can be tracked by collarette resolutionDEPTH panel consensus was obtained by using the Delphi methodology, an approach that allows experts to achieve...